ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0366

Active Joint Acoustic Emissions on the Achilles Tendon: A Digital Biomarker of Enthesitis Related Arthritis

Quentin Goossens1, Miguel Locsin2, Emily Moise3, Lori Ponder4, Omer Inan1 and Sampath Prahalad5, 1Georgia Institute of Technology, Atlanta, GA, 2Emory University School of Medicine, Atlanta, GA, 3Georgia Institute of Technolgy, Atlanta, GA, 4Children's Healthcare of Atlanta, Atlanta, GA, 5Emory University School of Medicine, Children's Pediatric Institute, Atlanta, GA

Meeting: ACR Convergence 2023

Keywords: Biomarkers, Inflammation, Juvenile idiopathic arthritis, Juvenile Rheumatoid Arthritis, Measurement

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0345–0379) Pediatric Rheumatology – Clinical Poster I: JIA

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a chronic condition in children that causes joint inflammation. Enthesitis-related arthritis (ERA), a subtype of JIA, affects 10-20% of patients and is characterized by enthesitis, leading to substantial joint pain and disability. Diagnosing JIA subtypes is challenging due to insensitive and subjective clinical examinations, patient surveys, non-specific laboratory tests and a lack of pediatric rheumatologists worldwide. Active joint acoustic emission (JAE) sensing, using vibrational stimulation, offers potential to assess the inflammatory status of soft tissues such as the Achilles tendon (AT). Integrating JAEs with machine learning (ML) algorithms can offer valuable insights into tendon health. The aim of this study is to demonstrate the utility of active JAEs as a new digital biomarker for assessing AT involvement in ERA.

Methods: JAEs were recorded from 14 patients diagnosed with JIA that were divided into two subgroups: (1)ERA and symptomatic AT enthesitis (sx ERA), and (2) without ERA and asymptomatic ATs (asx nERA). Symptomatic AT enthesitis was determined by tenderness on clinical examby a physician, while asymptomatic AT showed no tenderness, stiffness, or swelling. To record the JAEs, a setup comprising a miniature vibration motor and an accelerometer was used. The vibration motor provided a harmless input train of burst vibrations, while the accelerometer measured the response of the AT in tiptoe position. The recorded signals were filtered, and 25 bursts were segmented to extract 25 temporal features and the top 3 principal components(PC).Two MLclassifier (logistic regression) was trained using three most salient features and the second and third PCs, respectively. Two subject-wise cross-validation approaches were used to assess the model’s generalizability: leave-one-subject-out cross-validation (LOSO-CV) and a 3-fold cross-validation. The latter was performed 10 times with unique combinations to evaluate robustness.

Results: The feature-based LOSO-CV resulted in an 86% accuracy, 83% sensitivity and 88% specificity. The PC-based LOSO-CV resulted in a 71% accuracy, 67% sensitivity and 75% specificity. The corresponding confusion matrices, ROC curves and boxplot of the subject scores are shown in Figure 1. The iterations of the 3-fold cross-validation when considering the feature-based approach resulted in a 79% mean accuracy (range: 71-93%), a 70% mean sensitivity (range: 50-83%) and an 86% mean specificity (range 75-100%). When considering the PC-based classification, the 3-fold validation resulted in a 76% mean accuracy (range: 64-93%) a 72% mean sensitivity (range: 67-100%) and an 80% mean specificity (range 63-100%).

Conclusion: The presented results lay the foundation in recognizing the potential utility of active JAE technology to identify and label symptomatology on the entheses of the Achilles tendon. While more work needs to be done to increase the sample size and optimize the technology by using training labels validated by gold standard technology, JAEs hold promise as a screening or disease monitoring tool that can be used in clinic or at home and that may help decrease disease morbidity caused by JIA in children.

Supporting image 1

Figure 1 Results of the LOSO-CV. Top row: confusion matrices, middle row: ROC curves, bottom row: box plots of the subjects scores of the correctly predicted subjects generated by the classification algorithm. Left column shows the results of the feature-based classification, right column shows the results of the PC-based classification.


Disclosures: Q. Goossens: None; M. Locsin: None; E. Moise: None; L. Ponder: None; O. Inan: Arthroba, 4, 10, 11; S. Prahalad: None.

To cite this abstract in AMA style:

Goossens Q, Locsin M, Moise E, Ponder L, Inan O, Prahalad S. Active Joint Acoustic Emissions on the Achilles Tendon: A Digital Biomarker of Enthesitis Related Arthritis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/active-joint-acoustic-emissions-on-the-achilles-tendon-a-digital-biomarker-of-enthesitis-related-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/active-joint-acoustic-emissions-on-the-achilles-tendon-a-digital-biomarker-of-enthesitis-related-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology